key: cord-0952062-sk6jk96r authors: Chew, Michael; Tang, Zeyu; Radcliffe, Christopher; Caruana, Dennis; Doilicho, Natty; Ciarleglio, Maria M.; Deng, Yanhong; Tsao, Guadalupe Garcia- title: Significant liver injury during hospitalization for COVID-19 is not associated with liver insufficiency or death date: 2021-05-15 journal: Clin Gastroenterol Hepatol DOI: 10.1016/j.cgh.2021.05.022 sha: 4fbd15bbf623bcd0b93bc8b493aecd786e7b4127 doc_id: 952062 cord_uid: sk6jk96r Background and Aims COVID-19 is associated with hepatocellular liver injury of uncertain significance. We aimed to determine whether development of significant liver injury during hospitalization is related to concomitant medications or processes common in COVID-19 (e.g. ischemia, hyperinflammatory or hypercoagulable states) and to determine whether it can result in liver failure and death. Methods 834 consecutive patients hospitalized with COVID-19 were included. Clinical, medication and laboratory data were obtained at admission and throughout hospitalization using an identified database. Significant liver injury was defined as an AST≥ 5X ULN; ischemia was defined as vasopressor use for a minimum of 2 consecutive days; hyper-inflammatory state as hs-CRP ≥100mg/L and hypercoagulability as D-dimer ≥5mg/L, any time during hospitalization. Results 105 (12.6%) patients developed significant liver injury. Compared to those without significant liver injury, ischemia [OR 4.3 (2.5-7.4, p <0.0001)] and tocilizumab use [OR 3.6 (1.9-7.0, p=0.0001)] were independent predictors of significant liver injury. While AST correlated closely with ALT (R=0.89) throughout hospitalization, AST did not correlate with INR (R= 0.10) or with bilirubin (R=0.09). Death during hospitalization occurred in 136 (16.3%) patients. Multivariate logistic regression showed that significant liver injury was not associated with death [OR 1.4 (0.8-2.6, p=0.2)], while ischemic [OR 2.4 (1.4-4.0, p=0.001)] hypercoagulable [OR 1.7 (1.1-2.6, p=0.02)], and hyperinflammatory [OR 1.9 (1.2-3.1, p=0.02)] disease states were significant predictors of death. Conclusions Liver test abnormalities known to be associated with COVID-19 are secondary to other insults, mostly ischemia or drug-induced liver injury, and do not lead to liver insufficiency or death. In the liver, these receptors appear to be expressed mostly in cholangiocytes and, to a much lesser degree, in hepatocytes [1] . Liver histologic findings in patients who died from COVID-19 are predominantly steatosis and mild lobular/portal inflammation [2, 3] . These changes are non-specific and do not suggest cholestatic injury, as would be expected if SARS-CoV-2 led to cytopathic liver injury. Liver test abnormalities have been noted since early reports of COVID-19 in China [4] with pooled prevalence of 15% [5] and 19% [6] , while in the largest U.S. series, comprising 5700 patients, abnormal admission aspartate aminotransferase (AST) was reported in 58% of patients with only 2% having levels >15X the upper limit of normal (ULN) [7] . The most common abnormality consists of elevation in AST, being consistently higher than the alanine aminotransferase (ALT) and with higher levels observed in those with severe COVID-19 [8] [9] [10] [11] [12] . Alkaline phosphatase (AP) and serum total bilirubin (TBIL) levels are elevated in <15% of the patients on admission [9] . Therefore, clinically, the injury is mostly hepatocellular. Studies looking at peak liver test abnormalities during hospitalization have demonstrated that up to 83% of patients develop some abnormality in AST but most abnormalities are minor and <20% of them exceed 5X ULN [8] [9] [10] [11] 13, 14] . Higher and continued AST or ALT abnormalities are mostly observed in patients with severe COVID-19 [8] [9] [10] [11] 13, 14] and therefore, peak AST/ALT levels have been shown to be an independent predictor of death [8, 10, 14] . However, these rapid communications report on peak AST/ALT levels but did not correlate changes in aminotransferases occurring throughout hospitalization with concomitant events common in COVID-19 (such as ischemia, medications, and hyperinflammatory or hypercoagulable states) that could be associated with AST elevation. The objectives of the present study were to determine whether significant elevations in AST occurring during hospitalization in patients with COVID-19 are a) directly related to concomitant processes common in COVID-19 that could cause liver injury (thereby making direct liver injury less likely) and b) whether these significant AST elevations are associated with liver insufficiency and/or independently associated with death. Figure 1) . Sixty-five patients were excluded for various reasons (34 were admitted for reasons other than COVID-19 but had an incidental positive SARS-CoV-2 test, 15 had opted out, 11 had no liver tests, 3 had inconclusive SARS-CoV-2 results, and 2 were < 18 years old). Therefore, the study is based on a cohort of 834 patients admitted with COVID-19 who had at least one set of liver injury tests (AST, ALT, AP) and liver function tests (INR, TBIL, albumin). Patients were followed until June 26, 2020, thereby providing a minimum of 8 weeks of observation. This study was deemed exempt from regulatory requirements applicable to human subject research. Relevant clinical data was pulled from each unique hospitalization instance to generate the database. Admission demographic information included age, sex, race, ethnicity, history of diabetes, hypertension, coronary artery disease, obesity, obstructive lung disease, congestive heart failure and underlying liver disease. Comorbidities were determined based on ICD-9 and ICD-10 codes. Relevant laboratory tests were collected at admission and throughout hospitalization. The administration and timing of relevant medications at any time during hospitalization, including vasopressors and potentially hepatotoxic drugs (e.g. tocilizumab, antibiotics, lopinavir/ritonavir), were collected. Time of admission was subtracted from time-to-order to determine time elapsed from hospital admission to each order instance. All admission data, medication data, lab values and lab dates (initial, peak and most recent) were manually verified by chart review (MC, ZT, CR, ND, DC). Liver test abnormalities were defined based on the YNHH laboratory reference range standards (Supplementary Table 1 ). Because AST elevation is the most common abnormality in COVID-19 and J o u r n a l P r e -p r o o f based on ACG guidelines [15] , we defined significant liver injury as an AST elevated by ≥5X ULN at any time during hospitalization. In addition to medications, conditions/disease states that occur commonly during the course of COVID-19 and that could cause liver injury were defined as follows: ischemic injury was defined as use of vasopressors (norepinephrine, vasopressin, dopamine, and phenylephrine) for at least 2 consecutive days; hyperinflammatory state was defined as any hs-CRP 100 mg/L; and a hypercoagulable state was defined as any D-dimer 5 mg/L. Descriptive statistics were summarized using median and ranges for continuous variables and counts and proportions for categorical variables. To investigate factors independently associated with significant liver injury, relevant medications or disease states significantly associated with an AST>5X ULN at any time during hospitalization on univariate analysis (by Fisher's exact test for categorical variables, Wilcoxon rank sum test for continuous variables) were then analyzed using a multivariable logistic regression model (excluding variables that intercorrelated significantly). To investigate whether significant liver injury was an independent predictor of death, this and other medications/diseases states significantly associated with death on univariate analysis were analyzed using a multivariable logistic regression model (excluding variables that intercorrelated significantly). As sensitivity analyses, both models were further adjusted for potential confounders, specifically age, gender, race, BMI and comorbidites. Sensitivity analysis using ALT ≥5X ULN was also performed. P-values less than or equal to 0.05 were considered statistically significant. All analyses were conducted using SAS (version 9.4; Cary, NC) and R (version 3.6.2). Characteristics of the 834 patients included in the study are shown in There was a strong correlation (R=0.89) between changes in AST and changes in ALT over time ( Significant liver injury was observed in only 25 patients (3%) at the time of admission, however, it developed during hospitalization in 105 (12.6%) patients (Supplementary Table 3 ). Patients with significant liver injury were younger, more likely to be male, Black or Hispanic and to have higher aminotransferases on admission ( Table 1) . Table 2 , Patients with significant liver injury were sicker, as indicated by higher rates of ICU admission, intubation, treatment with steroids, vasopressors and tocilizumab. Patients with preexisting liver disease were not more likely to develop significant liver injury. On multivariable analysis, an ischemic state and tocilizumab use were the only two independent predictors of significant liver injury ( Table 2) . The same two predictors were identified when using ALT≥5X ULN as a marker of severe liver injury (Supplementary Table 4 ). Sensitivity analyses that further adjusted the multivariable model for potential confounders of age, gender, race and BMI gave identical conclusions (data not shown). To emphasize the relationship between significant liver injury and ischemia, in 29 patients with AST values for 3 time periods (up to 2 days before, during and up to 4 days after vasopressor discontinuation), were independent predictors of death. Significant liver injury (AST 5X ULN) was not an independent predictor of death (Table 3) . This finding was confirmed in sensitivity analyses that adjusted the multivariable model for baseline characteristics (age, gender, race, BMI, and comorbidities) (Supplementary Table 5 ) and in an analysis excluding 46 patients with single admission value of AST (Supplementary Table 6 ). The lack of an association with death was also identified when using ALT≥5X ULN as a marker of severe liver injury (Supplementary Table 7) AST throughout hospitalization did not correlate with any of the following: hs-CRP (R=0.04) or with Ddimer (R=0.15), INR (R=0.10) or total bilirubin (R=0.09). Of the 105 patients with significant liver injury, there were only 8 (7.6%) patients in whom peak AST was associated with an INR >1.5 as an indicator of liver failure (encephalopathy was not evaluable since all these patients were sedated). Characteristics of these patients are shown in Supplementary Table 8 . There was no significant difference in hospitalization status for those who were discharged, still admitted, or died at time of follow-up (p=0.3) between those with and without significant liver injury during hospitalization ( Table 2 ). The development of liver test abnormalities during hospitalization for COVID-19 are frequent. However, the pathophysiology of these abnormalities and their relationship to an increased mortality, visà-vis concomitant confounders (ischemia, medications, hyperinflammatory and/or hypercoagulable J o u r n a l P r e -p r o o f states), remains unclear. Abnormalities are predominantly hepatocellular and consistently show AST higher than ALT. This is unlike most viral hepatitides (hepatitis A, B or C) in which ALT is higher than AST. Conditions in which AST is higher than ALT are those that predominantly affect the hepatic centrilobular area such as alcoholic liver disease, drug-induced liver disease and ischemic injury, although in these conditions AST levels are generally higher than those noted in patients with COVID-19 [16] . Death from hepatocellular liver injury is always associated with liver insufficiency, which in the acute setting is indicated by an increased INR and hepatic encephalopathy. Despite thousands of patients with COVID-19 reported in the literature, there have only been two reports of acute hepatitis that could be ascribed to SARS-CoV-2 [17, 18] , only one of which developed severe acute hepatitis with liver failure (with prolonged INR and encephalopathy) with some histological evidence of viral hepatitis but without confirmatory viral inclusions and no liver PCR [18] . Aminotransferase abnormalities during COVID-19 are commonly mild with only 20% or so developing elevations in AST ≥5X ULN. The objectives of this study were to determine whether liver injury during hospitalization is more reflective of concomitant factors than direct liver injury by SARS-CoV-2, and whether this liver injury is independently related to death in patients with COVID-19. Several studies have looked specifically at abnormalities in liver tests during hospitalization [8] [9] [10] [11] 13, 14] . They were mostly rapid communications performed at the beginning of the pandemic that relied on deidentified data obtained from administrative databases without confirmation from medical record review and using admission data and/or peak abnormalities during hospitalization [8] [9] [10] . As in our study, all of them show that aminotransferase abnormalities are more marked in patients with severe COVID-19 (using different definitions of severity). Although a small study by Bloom et al [13] could not find any factor that would predict significant liver injury, larger studies identified peak ferritin and peak IL-6 [8] ; age, male gender, fever, dyspnea, GI symptoms, antibiotics, steroid, leukocyte and platelet counts [10] ; or preadmission AST and tocilizumab [9] . Regarding factors associated with death, the study by Phipps et [8] showed that age, diabetes, intubation and peak ALT were independent predictors of death while the study by Lei et al [10] showed that, compared to other liver tests, peak AST was associated with J o u r n a l P r e -p r o o f the highest risk of death. However, variables were analyzed in these studies without accounting for intercorrelations among them. Our study is the first to correlate pathophysiologically-relevant disease states during COVID-19 that could potentially be associated with significant liver injury during hospitalization and to establish intercorrelations among predictive variables. We defined significant liver injury using an AST> 5xULN and, although one can argue that the source of AST is the muscle, our demonstration of a very close correlation between AST and ALT and previous data showing a lack of correlation between AST and creatine kinase, minimize this possibility for the majority of the cases. Ischemic liver injury results from global decrease in blood flow to the liver associated with hypotension and therefore we considered vasopressor use as a surrogate for ischemic liver injury [19] . Because most of the patients on vasopressors were also intubated this would also add to the possibility of ischemic damage due to hypo-oxygenation. Initially, we had considered any use of vasopressors (in 133 patients) during hospitalization but realized that some patients had received only one dose of vasopressors and therefore changed our definition to include 102 patients who had been on vasopressors for at least 2 consecutive days. The so defined ischemic state was the most important predictor of significant liver injury in our study and a significant predictor of death (independent of AST). Of note, results using the original definition of ischemia were not different (results not shown). It has also been proposed that the liver injury could be from a hyperinflammatory state that is characterized by immune dysregulation and hypercytokinemia resulting in cytokine storm syndrome (CSS) [20] . Although IL-6 elevations were only modest in our study and not at levels described in other CSS such as in chimeric antigen T-cell therapy where it exceeds 1000 pg/mL, we decided to incorporate a marker of hyperinflammation given the finding of a high ferritin (another marker of inflammation) as a predictor of liver injury in the study by Phipps et al [8] . However, because there was a significant correlation between ferritin, IL-6 and hs-CRP we defined it solely as a hs-CRP level >100mg/L. While hs-CRP levels did not correlate with AST levels throughout hospitalization and was not predictive of significant liver injury, the inflammatory state was predictive of death as has been shown in other studies [13, 21] . Another potential cause of liver injury is a hypercoagulable state that has been also associated with severe disease potentially resulting in microthrombi [22] [23] [24] that could affect liver blood flow. We initially defined the hypercoagulable state as increased D-dimer and fibrinogen level but because these tests also correlated significantly, we defined it solely as a D-dimer 5 mg/L throughout hospitalization. Although the hypercoagulable state was not predictive of significant liver injury it was associated with mortality. To investigate drug-induced liver injury (DILI) we looked at all medications used during hospitalization. Drugs commonly used in patients with COVID-19 known to cause DILI are tocilizumab [9, 25] , lopinavir/ritonavir [9, 25, 26] , hydroxychloroquine [9, 25] , remdesivir [8, 25, 27 ] and antibiotics. Because most patients on pressors were on antibiotics and the classes of antibiotics varied, they were not incorporated in multivariate models. On univariate analysis both tocilizumab and remdesivir were significantly more common in patients with significant liver injury. Remarkably, and similar to the study by Hundt et al, we found tocilizumab use to be an independent predictor of significant liver injury but not of death [9] . One of the main issues is the association between significant liver injury during hospitalization and death in patients with COVID-19. We found that significant liver injury was not an independent predictor of death while disease states associated with COVID-19 (ischemic, hyperinflammatory and hypercoagulable) were predictive. Furthermore, AST levels did not correlate with INR indicating that abnormalities were not associated with liver insufficiency. In detailing the characteristics of only 8 patients with AST levels >15X ULN associated with an INR >1.5, all had an abnormal serum creatinine (ranging from 1.8 to 7.1), which suggests the liver injury was part of a multiorgan failure state. In conclusion, although direct viral injury cannot be entirely excluded, our study indicates that concomitant factors, mainly ischemia and drug-induced liver injury play a major role in the pathogenesis of significant liver injury during COVID-19. Perhaps more importantly, this liver injury is not directly associated with liver insufficiency or death. Values reported as median (ranges) unless otherwise specified. Ischemic state = vasopressor use for at least 2 days; hyperinflammatory state = any hs-CRP ≥ 100mg/L; hypercoagulable state = any D-dimer 5 mg/L. Because all patients on vasopressors were in ICU and most were intubated and on antibiotics and/or hydroxychloroquine, these variables were not entered in the multivariable model. SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19 Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data Liver histopathology in severe COVID 19 respiratory failure is suggestive of vascular alterations Clinical Characteristics of Coronavirus Disease 2019 in China AGA Institute Rapid Recommendations for Gastrointestinal Procedures During the COVID-19 Pandemic Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area Acute Liver Injury in COVID-19: Prevalence and Association with Clinical Outcomes in a Large US Cohort Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1827 Patients in a Major U.S. Hospital Network Longitudinal Association Between Markers of Liver Injury and Mortality in COVID-19 in China Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2 positive patients Clinical Features of COVID-19-Related Liver Functional Abnormality Liver Biochemistries in Hospitalized Patients With COVID-19 The association between markers of liver injury and clinical outcomes in patients with COVID-19 in Wuhan ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Standard liver tests COVID-19 Presenting as Acute Hepatitis COVID-19 presenting as fulminant hepatic failure: A case report Gastrointestinal disorders of the critically ill. Shock liver Confronting the controversy: Interleukin-6 and the COVID-19 cytokine storm syndrome COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study Liver Injury in COVID-19 is Associated with Endothelial Mediated Hypercoagulability Driven by IL-6 Trans-Signaling Current Overview on Hypercoagulability in COVID-19 Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement